Dallas : Moderna and Pfizer’s COVID-19 Vaccine Landscape Is “Pretty Promising” But Caution Is Required

November 20, 2020 – The World Health Organization is “very happy” and “encouraged” by the preliminary positive results of the Covid-19 vaccines from the companies Moderna and Pfizer, but warned that final data and follow-up of the effects are yet to be awaited. adverse effects in patients after clinical trials are completed.

“We are very happy to hear about this good news, but there are many other candidate vaccines that will deliver results before the end of the year and the beginning of the next, and some will be easier to distribute at the country level and others more complicated. The outlook it is quite promising and having two candidates with more than 90% effectiveness is very encouraging, but there are still many challenges in the implementation, “said Dr. Mariangela Simao, an expert in vaccines and treatments, during the Organization’s bi-weekly conference.

Dallas Covid-19

Listen to the audio of the interview at the following link: Click here.

Pfizer He called on U.S. regulatory authorities on Friday to allow him emergency use of his COVID-19 vaccine, thereby unleashing a possible countdown to a process that could bring first vaccines to the public – in limited quantities in December. .

The announcement came several days after Pfizer and its German partner BioNTech announced that their vaccine appears to be 95% effective in preventing mild to severe COVID-19 disease during an ongoing study.

The companies argued that the vaccine must qualify for emergency use authorization, something the Food and Drug Administration can grant before the final testing is fully concluded, the Dallas Morning News reported. In addition to the FDA filing, they have already started filing applications in Europe and the UK.

“We are very happy to hear about this good news, but there are many other candidate vaccines that will deliver results before the end of the year and the beginning of the next, and some will be easier to distribute at the country level and others more complicated. The outlook it is quite promising and having two candidates with more than 90% effectiveness is very encouraging, but there are still many challenges in the implementation, “said Dr. Mariangela Simao, an expert in vaccines and treatments, during the Organization’s bi-weekly conference.

Dallas ISD

Dallas Covid-19

Listen to the audio of the interview at the following link: Click here.

Pfizer He called on U.S. regulatory authorities on Friday to allow him emergency use of his COVID-19 vaccine, thereby unleashing a possible countdown to a process that could bring first vaccines to the public – in limited quantities in December. .

The announcement came several days after Pfizer and its German partner BioNTech announced that their vaccine appears to be 95% effective in preventing mild to severe COVID-19 disease during an ongoing study.

The companies argued that the vaccine must qualify for emergency use authorization, something the Food and Drug Administration can grant before the final testing is fully concluded, the Dallas Morning News reported. In addition to the FDA filing, they have already started filing applications in Europe and the UK.